Zacks Research Has Negative Outlook of GSK Q1 Earnings

GSK plc (NYSE:GSK) – Analysts at Zacks Research reduced their Q1 2025 earnings per share estimates for shares of GSK in a research report issued to clients and investors on Wednesday, December 11th. Zacks Research analyst E. Bagri now expects that the pharmaceutical company will earn $1.10 per share for the quarter, down from their prior estimate of $1.11. The consensus estimate for GSK’s current full-year earnings is $4.02 per share. Zacks Research also issued estimates for GSK’s Q3 2025 earnings at $1.33 EPS, Q4 2025 earnings at $0.79 EPS, FY2025 earnings at $4.24 EPS and FY2026 earnings at $4.73 EPS.

Several other equities analysts have also weighed in on GSK. Deutsche Bank Aktiengesellschaft lowered shares of GSK from a “buy” rating to a “hold” rating in a report on Friday, November 15th. Barclays raised GSK to a “hold” rating in a research note on Tuesday, August 27th. Guggenheim cut GSK from a “buy” rating to a “neutral” rating in a research note on Thursday, October 31st. Jefferies Financial Group downgraded GSK from a “buy” rating to a “hold” rating and decreased their price objective for the company from $53.00 to $39.50 in a report on Tuesday, November 12th. Finally, StockNews.com upgraded GSK from a “buy” rating to a “strong-buy” rating in a report on Thursday. Seven analysts have rated the stock with a hold rating and four have given a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $43.25.

GSK Stock Down 0.7 %

GSK stock opened at $33.95 on Friday. The company has a market capitalization of $70.35 billion, a PE ratio of 22.19, a PEG ratio of 1.54 and a beta of 0.64. GSK has a 12-month low of $32.83 and a 12-month high of $45.92. The firm’s fifty day moving average is $36.28 and its 200 day moving average is $39.36. The company has a quick ratio of 0.53, a current ratio of 0.81 and a debt-to-equity ratio of 0.98.

GSK Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, January 9th. Investors of record on Friday, November 15th will be given a dividend of $0.3928 per share. This is a boost from GSK’s previous quarterly dividend of $0.38. The ex-dividend date is Friday, November 15th. This represents a $1.57 annualized dividend and a dividend yield of 4.63%. GSK’s payout ratio is presently 99.35%.

Insider Buying and Selling

In other news, major shareholder Plc Gsk purchased 2,791,930 shares of the business’s stock in a transaction that occurred on Friday, September 27th. The shares were acquired at an average cost of $8.00 per share, for a total transaction of $22,335,440.00. Following the completion of the acquisition, the insider now owns 16,775,691 shares in the company, valued at $134,205,528. This trade represents a 19.97 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 10.00% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On GSK

Several hedge funds have recently modified their holdings of GSK. Eastern Bank purchased a new stake in shares of GSK during the third quarter valued at approximately $26,000. Sunbelt Securities Inc. increased its position in shares of GSK by 73.8% during the 3rd quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company’s stock valued at $29,000 after purchasing an additional 302 shares during the last quarter. Concord Wealth Partners raised its stake in shares of GSK by 231.8% during the 3rd quarter. Concord Wealth Partners now owns 783 shares of the pharmaceutical company’s stock worth $32,000 after purchasing an additional 547 shares during the period. Ashton Thomas Private Wealth LLC purchased a new position in shares of GSK in the 2nd quarter worth about $37,000. Finally, Fortitude Family Office LLC bought a new position in GSK during the third quarter valued at about $42,000. Institutional investors own 15.74% of the company’s stock.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.